X
[{"orgOrder":0,"company":"Anchiano Therapeutics, Inc","sponsor":"ChemomAb","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Anchiano Therapeutics and Chemomab Announce Entry Into Definitive Merger Agreement","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II\/ Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2020","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II\/ Phase III"},{"orgOrder":0,"company":"Anchiano Therapeutics, Inc","sponsor":"Cormorant Asset Management","pharmaFlowCategory":"D","amount":"$45.5 million","upfrontCash":"Undisclosed","newsHeadline":"Anchiano Announces Shareholder Approval of the Merger with Chemomab and Prices $45.5M Private Financing","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II\/ Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2021","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II\/ Phase III"},{"orgOrder":0,"company":"Anchiano Therapeutics, Inc","sponsor":"ChemomAb","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Chemomab Completes Merger with Anchiano Therapeutics","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II\/ Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2021","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II\/ Phase III"}]
Find Clinical Drug Pipeline Developments & Deals by Anchiano Therapeutics, Inc
Filters
Companies By Therapeutic Area
Details:
Chemomab expects to use net proceeds from this private placement to advance in parallel three Phase 2 clinical trials for its lead product, CM-101, a novel antibody for treating rare fibrotic conditions, as well as to further develop its earlier-stage pipeline.
Lead Product(s):
CM-101
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder)
Product Name: CM-101
Highest Development Status: Phase II/ Phase III
Product Type: Large molecule
Partner/Sponsor/Collaborator:
ChemomAb
Deal Size: Undisclosed
Upfront Cash: Undisclosed
Deal Type: Merger
March 16, 2021
Details:
Financing will be used to advance the Chemomab pipeline. Chemomab developed CM-101, a monoclonal antibody designed to bind and block CCL24 activity.
Lead Product(s):
CM-101
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder)
Product Name: CM-101
Highest Development Status: Phase II/ Phase III
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Cormorant Asset Management
Deal Size: $45.5 million
Upfront Cash: Undisclosed
Deal Type: Financing
March 15, 2021
Details:
Merger brings lead compound CM-101, a first in class anti-CCL24 antibody into advanced clinical development for fibrosis-related diseases with significant unmet medical need.
Lead Product(s):
CM-101
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder)
Product Name: CM-101
Highest Development Status: Phase II/ Phase III
Product Type: Large molecule
Partner/Sponsor/Collaborator:
ChemomAb
Deal Size: Undisclosed
Upfront Cash: Undisclosed
Deal Type: Merger
December 15, 2020